|
Sign In to gain access to subscriptions and/or personal tools.
|
Use of Transgenic Mice in Carcinogenicity Hazard Assessment
David Jacobson-Kram
Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20850, USA, jacobsonkram{at}cder.fda.gov
Frank D. Sistare
Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20850, USA
Abigail C. Jacobs
Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20850, USA
Determining the carcinogenic potential of materials to which humans have significant exposure is an important, complex and imperfect exercise. Not only are the methods for such determinations protracted, expensive and utilize large numbers of animals, extrapolation of data from such studies to human risk is imprecise. Toxicologists have long recognized these shortcomings but the 2-year chronic rodent study has remained the gold standard. Recent developments in the field of molecular oncology and development of methods to insert or inactivate specific genes in animals have provided the tools with which to develop the next generation of carcinogenicity assays. With improved understanding of oncogene activation and tumor suppressor gene inactivation a number of animal models have been developed to dramatically reduce latency for chemically induced cancers. This has led to the development of shorter carcinogenicity assays. Also, because the spontaneous tumor frequencies in these animals are low during the in-life portion of the study, and studies are terminated well before the health complications of advanced aging are observed, it has been possible to reduce the group sizes and reduce animal usage. FDA's adoption of ICH S1B in 1997, (ICH, 1997) "Testing for the Carcinogenicity of Pharmaceuticals," opened the door for the use of such transgenic models in regulatory toxicology. This presentation reviews the current state of the science and its application to regulatory issues.
Key Words: Carcinogenicity testing • transgenic mice • p53 • Tg.AC • TgrasH2 • regulatory toxicology.
References
- Boley, S.E., Anderson, E.E., French, J.E., Donehower, L.A., Walker, D.B., and Recio, L. (2000). Loss of p53 in benzene-induced thymic lymphomas in p53 mice: evidence of chromosomal recombination Cancer Res 60, 2831—5.[Abstract/Free Full Text]
- Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A.J., Butel, J.S., and Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356, 215—21.[CrossRef][Medline]
[Order article via Infotrieve]
- Hansen, L.A., and Tennant, R.W. (1994). Follicular origin of epidermal papillomas in v-Ha-ras transgenic Tg.AC mouse skin. Proc Natl Acad Sci USA 91, 7822—6.[Abstract/Free Full Text]
- ILSI/HESI Alternatives to Carcinogenicity Testing Project. (2001). Toxicol Pathol 29, 1—198.[Free Full Text]
- International Conference on Harmonization, Expert Working Group on Safety (1997). Guidance for Industry S1B Testing for Carcinogencity of Pharmaceuticals,
 www.fda.gov/cder/guidance/index.htm . ICH, Geneva, Switzerland. - Jacobson-Kram, D., Gulezian, D., Wenk, M.L., Lanning, L.L., and Smith, G.B. (2003). Twenty six-week validation study of the Tg.rasH2 mouse test system using three carcinogens. Toxicologist 72, 1—S.
- Leder, A., Kuo, A., Cardiff, R., Sinn, E., and Leder, P. (1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc Natl Acad Sci USA 87, 9178—82.[Abstract/Free Full Text]
- Pritchard, J.B., French, J.E., Davis, B.J., and Haseman, J.K. (2003). The role of transgenic mouse models in carcinogen identification. Environ Health Perspect 111, 1—11.[Web of Science][Medline]
[Order article via Infotrieve]
- Saitoh, A., Kimura, M., Takahashi, R., Yokoyama, M., Nomura, T., Izawa, M., Sekiya, T., Nishimura, S., and Katuski, M. (1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene 5, 1195—1200.[Web of Science][Medline]
[Order article via Infotrieve]
- Sistare, F.D., and Jacobs, A.C. (2003). Use of transgenic animals in regulatory carcinogenicity evaluations. In Alternative Toxicological Methods (H. Salem and S. A. Katz, eds.), pp. 391—412. CRC Press, Boca Raton, FL.
- Van Kreijl, C.F., McAnulty, P.A., Beems, R.B., Vynckier, A., van Steeg, H., Fransson-Steen, R., Alden, C.L., Forster, R., van der Laan, J.-W., and Vandenberghe, J. (2001). Xpa and Xpa/p53 Knockout mice: overview of available data. Toxicol Pathol 29, 117—27.[Abstract/Free Full Text]
- Van Steeg, H., de Vries, A., van Oostrom, C.T.M., van Benthem, J., Beems, R.B., and van Kreijl, C.F. (2001). DNA repair-deficient Xpa and Xpa/p53Knockout mice: nature of the models. Toxicol Pathol 29, 109—16.[Abstract/Free Full Text]
- Venkatachalam, S., Tyner, S.D., Pickering, C.R., Boley, S., Recio, L., Frech, J.E., and Donehower, L.A. (2001). Is p53 haplo insufficient for tumor suppression? Implications for the p53 mouse model in carcinogenicity testing. Toxicol Pathol 29, 147—54.[Abstract/Free Full Text]
- Youssef, A.F., Borellini, F., Jacobson-Kram, D., and Fort, F. (2001). Analysis for loss of heterozygosity (LOH) of p53 allele in tumors derived from p53 and CD-1 mice following repeated subcutaneous injections of solutions containing antioxidants. Environ Molec Mutagen37, 27—30.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Toxicologic Pathology, Vol. 32, No. 1 suppl,
49-52 (2004)
DOI: 10.1080/01926230490424761
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Morton, K. L. Bailey, C. L. Stout, R. J. Weaver, K. A. White, M. J. Lorenzen, and D. J. Ball
N-Methyl-N-Nitrosourea (MNU): A Positive Control Chemical for p53+/- Mouse Carcinogenicity Studies
Toxicol Pathol,
December 1, 2008;
36(7):
926 - 931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
